Law Change Would Help Kolon As It Progresses Pipeline
This article was originally published in PharmAsia News
Kolon life Science expects South Korea’s government to ease gene therapy rules to help the company launch its osteoarthritis drug in the domestic market, and is looking to complete licensing talks with potential global partners before the product's launch, the venture said at a recent investors’ meeting.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Hanmi Pharm is remaining upbeat after Sanofi’s decision to find another commercialization partner for efpeglenatide, saying it was the best strategy for the long-acting GLP-1 agonist given the strategic change in the big pharma’s diabetes strategy.
GemVax unveils positive topline results for South Korean Phase II study of novel peptide drug targeting patients with moderate to severe Alzheimer’s disease, raising hopes for the upcoming US trials.